Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India - LARVOL DELTA

Reactogenicity and Immunogenicity following Heterologous and Homologous Third Dose COVID-19 vaccination in UK Adolescents (Com-COV3): A Randomised Controlled Non-Inferiority Trial. (PubMed, J Infect) - "All booster regimens evaluated elicited a robust immune response. 10μg fractional adult BNT162b2 vaccine demonstrated similar immunogenicity compared with 30μg BNT162b2 and superior immunogenicity compared with 10μg paediatric BNT162b2 vaccine. Fractional doses of the adult BNT162b2 vaccine are an alternative to the paediatric formulation for booster campaigns in adolescents."

Head-to-Head • Journal • Infectious Disease • Meningococcal Infections • Novel Coronavirus Disease • Pediatrics • Respiratory Diseases

Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trial. (PubMed, J Infect Dis) - P1 | "Cases of confirmed COVID-19 infection during the study were also examined...UQSC2 was equally well tolerated to the authorised comparator vaccine and produced an equally robust boost in neutralising immune response. These findings support the effectiveness of the MC2 platform in producing vaccines against newly emerging variants of SARS-CoV-2, and other respiratory viruses, as well as the platform's potential use in emergency response to novel viruses."

Journal • P1 data • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Parental Vaccine Hesitancy in Children With Comorbidities: A Comparative Analysis (ISPOR-EU 2025) - "Given the heightened vulnerability for severe outcomes in CCIC to vaccine-preventable diseases, understanding and addressing PVH in this population is critical. A targeted search of PubMed and EMBASE up to 16 May 2025 identified studies that assessed PVH for general childhood and pediatric COVID-19 vaccines... There is an observed higher prevalence of parental vaccine hesitancy among parents of CCIC compared to parents of healthy children, with variations observed across different health conditions. Targeted interventions emphasizing enhanced healthcare provider communication and condition-specific, evidence-based information are essential to address parental concerns and improve vaccine uptake in these vulnerable pediatric populations."

Clinical • Autism Spectrum Disorder • Bone Marrow Transplantation • Diabetes • Genetic Disorders • Hematological Malignancies • Hepatology • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Ophthalmology • Pediatrics • Renal Disease • Type 1 Diabetes Mellitus

Supporting equitable booster strategies: one-year real-world immunogenicity data in people with HIV (PWH) receiving different variant-adapted COVID-19 vaccines. (PubMed, Int J Infect Dis) - "Overall, mRNA boosters provided a stronger early humoral response, while Nuvaxovid may promote more sustained T-cell immunity. Both maintained robust responses over 12 months, supporting their use in PWH. Given its thermostability and accessibility, Nuvaxovid is a practical alternative when mRNA vaccines are unavailable or contraindicated."

Journal • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Precautionary Health Behaviours as Potential Confounders in COVID-19 Vaccine Effectiveness Studies. (PubMed, Vaccines (Basel)) - " PHBs should be considered a possible confounder of COVID-19 VE studies. Further research is needed to define when PHBs should be integrated into VE models, as the level of confounding may differ according to the study population and the epidemiological context."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccine. (PubMed, Clin Infect Dis) - "Post-vaccination NVX-CoV2373 antibody levels are stronger predictors of severe COVID-19 than any-severity Delta COVID-19. Low antibody responses indicate vulnerability to severe COVID-19."

Journal • Infectious Disease • Novel Coronavirus Disease • KEAP1

Matrix-M adjuvant - A key adjuvant in global vaccine development (ASTMH 2025) - "Early distribution to draining lymph nodes produces long-lasting memory B-cells and broad-based T-cell immunity.1 Matrix-M-containing vaccines are immunogenic and safe in both pediatric [e.g., malaria (R21/MM)2 and COVID-193] and adult populations [e.g., malaria (R21/MM),4,5 COVID-19, influenza,6 and Ebola7]...Additional experiments are underway to better understand the mechanisms of action and utility of Matrix-M in conjunction with various vaccine platforms and across different formulations. (Note: references available upon request)"

Clinical • Infectious Disease • Influenza • Malaria • Novel Coronavirus Disease • Pediatrics • Respiratory Diseases

Detection of Anti-SARS-CoV-2 Mucosal Immunoglobulin A in Clinical Saliva Samples After a Dose of Novavax COVID-19 Vaccine. (PubMed, J Med Virol) - P3 | "These participants had previously received ≥ 2 mRNA-based COVID-19 vaccinations prior to enrollment and received a single intramuscular study dose of NVX-CoV2601 (XBB.1.5) or bivalent vaccine (NVX-CoV2601 + NVX-CoV2373 [Wuhan]). Furthermore, cross-reactivity by identification of anti-JN.1 and anti-Wuhan IgA was also observed. The detection of IgA in clinical mucosal samples using this assay will be a valuable tool in supporting vaccine development."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 update: 2025-2026 vaccine formulations and recommendations. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease

Difference in reactogenicity events between mRNA and Protein-subunit Vaccines: Results from the Booster Epidemiological Evaluation of Health, Illness, and Vaccine Efficacy (BEEHIVE) Study, a U.S. randomized trial of 2023-2024 COVID-19 vaccines (XBB.1.5) (IDWeek 2025) - No abstract available

Clinical • Infectious Disease • Novel Coronavirus Disease

Effectiveness of NVX-CoV2373 and BNT162b2 COVID-19 Vaccination in South Korean Adolescents. (PubMed, Pediatr Infect Dis J) - "These results suggest that NVX-CoV2373 may provide more robust protection against medically attended COVID-19 as a third dose, compared with BNT162b2. While the aHR for the primary series also indicated lower risk with NVX-CoV2373, this difference was not statistically significant."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19: Efficacy and Safety of NVX-CoV2705 (clinicaltrials.gov) - P4 | N=6500 | Not yet recruiting | Sponsor: Novavax

New P4 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines. (PubMed, Cell Rep) - P1, P1/2 | "High-resolution cryo-EMPEM studies reveal extensive pAb responses to and around the supersite, with unique angles of approach and engagement. NTD supersite pAbs are also the most susceptible to variant mutations compared to other specificities, indicating that ongoing Spike ectodomain-based vaccine design strategies should consider immuno-masking this site to prevent induction of these strain-specific responses."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 open-label trial. (PubMed, Vaccine) - P3 | "The two NVX-CoV2373 boosters induced durable anti-SARS-CoV-2 immune responses up to 1 year after each dose and are therefore expected to persistently protect against SARS-CoV-2 infections and severe disease outcomes in Japanese adults. No new safety concerns were identified, demonstrating the expected acceptable safety profile in healthy Japanese participants."

Journal • P3 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial. (PubMed, J Infect) - P3 | "A BNT162b2 third dose booster dose in individuals primed with two doses of NVX-COV2373 is safe and induces strong and durable immunogenic responses, higher than seen in other comparable studies. These findings support the use and investigation of heterologous booster strategies and early investigation of heterologous vaccine technology schedules should be a priority in the development of vaccines against new pathogens."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine (clinicaltrials.gov) - P3 | N=9320 | Active, not recruiting | Sponsor: Novavax | Trial completion date: Feb 2026 ➔ Sep 2026 | Trial primary completion date: May 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Evaluating vaccination dosing strategies for SARS-CoV-2 in patients at high-risk for allergic reactions: Insights from vaccination campaign. (PubMed, World Allergy Organ J) - "The COVID-19 pandemic significantly increased the demand for allergy consultations to evaluate the risk of hypersensitivity reactions in patients either before receiving their first dose of an anti-SARS-CoV-2 vaccine (Group 1) or following suspected allergic reactions after vaccination (Group 2)...The rate of confirmed excipient allergy was very low, and vaccine adherence was comparable to the general population. This is, to our knowledge, the first study to longitudinally assess the number and types of vaccine doses administered to high-risk allergic individuals."

Journal • Allergy • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Real-world effectiveness of NVX-CoV2373 and BNT162b2 mRNA COVID-19 vaccination in South Korea. (PubMed, Vaccine) - "NVX-CoV2373 demonstrated favorable and similar effectiveness against any and severe SARS-CoV-2 infection, respectively, compared with BNT162b2, with evidence of enhanced NVX-CoV2373 durability."

Journal • Real-world evidence • Critical care • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Response to Letter to Editor "Advantage of the protein-subunit SARS-CoV-2 vaccines, MVC-CoV1901 and NVX-CoV2373". (PubMed, J Formos Med Assoc) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 update: Full approval for Novavax COVID-19 vaccine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease

Advantage of the protein-subunit SARS-CoV-2 vaccines, MVC-CoV1901 and NVX-CoV2373. (PubMed, J Formos Med Assoc) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 Reactogenicity (clinicaltrials.gov) - P4 | N=1000 | Not yet recruiting | Sponsor: Marcel Curlin

New P4 trial • Infectious Disease • Novel Coronavirus Disease

Anti-Spike IgG4 and Fc Effector Responses: The Impact of SARS-CoV-2 Vaccine Platform-Specific Priming and Immune Imprinting. (PubMed, J Infect) - "This effect was partially overcome by updated XBB.1.5 protein subunit vaccination, but not ancestral vaccine strains. We establish correlation of anti-S IgG4 responses to reduced nAbs and surrogate Fc effector functions and demonstrate the impact of additional booster vaccination on subsequent immune response and Fc effector functions in the context of ancestral and XBB.1.5 strains."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Potential protective advantage of the protein-subunit SARS-CoV-2 vaccines, MVC-CoV1901 and NVX-CoV2373, in patients with rituximab-treated immune-mediated inflammatory diseases: Real-world evidence. (PubMed, J Formos Med Assoc) - "Since the COVID-19 pandemic, patients with immune-mediated inflammatory diseases (IMID) are recommended to receive SARS-CoV-2 vaccinations to reduce complications following COVID-19 infection...Moreover, our data supports heterologous vaccine regimens incorporating protein-subunit vaccines as a viable strategy for patients with IMID. Given the small sample size, further studies are needed to validate the clinical implications of this study."

HEOR • Journal • Real-world evidence • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases

The Bioengineering of Insect Cell Lines for Biotherapeutics and Vaccine Production: An Updated Review. (PubMed, Vaccines (Basel)) - "Our manuscript discusses the history of developing insect cell lines, presents various recombinant protein production systems utilizing these cells, and summarizes modifications aimed at improving insect cell lines for recombinant protein biomanufacturing. Finally, we explore their implications in pharmaceutical production, particularly on Nuvaxovid®/Covovax, which is the latest approved vaccine developed using insect cell BEVSs for protection against SARS-CoV-2."

Journal • Preclinical • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNB1